Enterprise Value

11.1M

Cash

9.252M

Avg Qtr Burn

-11.15M

Short % of Float

0.67%

Insider Ownership

19.07%

Institutional Own.

7.51%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Tuspetinib mono/combo w/ Venetoclax Details
Acute myeloid leukemia, Cancer, Leukemia, Relapsed/refractory acute myeloid leukemia

Phase 1/2

Data readout

Luxeptinib (CG-806) (BTK and FLT3 Inhibitor) Details
Non-Hodgkin lymphoma, Chronic lymphocytic leukemia, Acute myeloid leukemia, Cancer

Phase 1/2

Update

Tuspetinib / Venetoclax /HMA triplet Details
Acute myeloid leukemia, Cancer, Leukemia, Relapsed/refractory acute myeloid leukemia

Phase 1/2

Initiation

APTO-253 (MYC inhibitor) Details
Acute myeloid leukemia, Cancer, Myelodysplastic syndrome

Failed

Discontinued

Tuspetinib (HM43239) & luxeptinib Details
Acute myeloid leukemia, B-cell malignancies, Relapsed/refractory acute myeloid leukemia

Failed

Discontinued